Prospective pharmacodynamic study on patients with moderate, active Crohn's disease treated with Rifaximin-EIR 400 mg tablets

Trial Profile

Prospective pharmacodynamic study on patients with moderate, active Crohn's disease treated with Rifaximin-EIR 400 mg tablets

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2013

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms RETIC-PD
  • Sponsors Alfa Wassermann SpA
  • Most Recent Events

    • 07 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top